Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Assets (2016 - 2025)

Historic Current Assets for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $2.5 billion.

  • Neurocrine Biosciences' Current Assets rose 4626.89% to $2.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year increase of 4626.89%. This contributed to the annual value of $2.5 billion for FY2025, which is 4626.89% up from last year.
  • Neurocrine Biosciences' Current Assets amounted to $2.5 billion in Q4 2025, which was up 4626.89% from $2.2 billion recorded in Q3 2025.
  • Neurocrine Biosciences' 5-year Current Assets high stood at $2.5 billion for Q4 2025, and its period low was $1.0 billion during Q3 2021.
  • In the last 4 years, Neurocrine Biosciences' Current Assets had a median value of $1.6 billion in 2023 and averaged $1.6 billion.
  • In the last 5 years, Neurocrine Biosciences' Current Assets plummeted by 1306.94% in 2021 and then skyrocketed by 4626.89% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Current Assets stood at $1.0 billion in 2021, then soared by 59.79% to $1.6 billion in 2023, then rose by 7.32% to $1.7 billion in 2024, then soared by 46.27% to $2.5 billion in 2025.
  • Its last three reported values are $2.5 billion in Q4 2025, $2.2 billion for Q3 2025, and $1.7 billion during Q2 2025.